Skip to main content

Table 6 AE type and outcomes for AEs grade 5 (fatal)

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

  Age Sex Gene Indication for treatment Pulmonary AVMs Treatment response Treatment duration at event Fatal event (SOC) Drug-related AE?
  Bleeding Support Mean Hemoglobin (Hb)  
BZB 67 Male ENG Refractory GI bleeding Regular blood transfusions < 6 g/dL Previously treated, no follow up for 5 ys Excellent, mean Hb > 10 g/dL 65 months Haemoptysis from ruptured PAVM (Vasc Disord) Possibly related ; theoretical alternate cause: spontaneous rupture
TH 69 Male ACVRL1 Refractory epistaxis Regular blood transfusions < 7 g/dL no Good: mean Hb > 9 g/dL; fewer tx 10 months Cardiac failure (Card Disord) Possibly related; theoretical alternate cause: ischemic cardiopathy
62 Male ENG Refractory GI bleeding Regular blood transfusions < 7 g/dL no Partial, mean Hb > 8 g/dL; fewer tx 23 months Ischemic stroke (Vasc Disord) possibly related; theoretical alternate cause: atherosclerosis
78 Male ENG Refractory epistaxis Regular blood transfusions < 7 g/dL no Good: mean Hb > 9 g/dL; fewer tx 2 months Catastrophic epistaxis (Resp Disord) possibly related; theoretical alternate cause: spontaneous nosebleed
  1. Legend: Drug dosing schedules provided in the text. SOC System Organ Classification